Asparaginase is an essential treatment for acute lymphoblastic leukemia – the most common malignant disease in children – with AP as a common adverse event occurring in about 5–10% of cases, which is the most frequent cause of discontinuing the asparaginase treatment [7]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.